Programs targeting Gram-positive pathogens

About Telum Therapeutics

Telum Therapeutics is a private, preclinical-stage biotech addressing the global antimicrobial resistance (AMR) crisis. Its core innovation is the APEXp® platform, which uses synthetic biology and AI to engineer phage lytic enzymes as targeted alternatives to traditional antibiotics. The company's pipeline targets high-priority, multidrug-resistant Gram-negative and Gram-positive pathogens, positioning it in a critical and growing market. As a pre-revenue entity, its success hinges on advancing its lead programs through clinical validation and securing strategic partnerships or funding.

Therapeutic Areas